Disease Von Hippel-Lindau: About A Case and Review of the Literature
A. El Ouafi*, F. El Alami, A. Bouzidi, S. Iferkhas, A. Laktaoui
Ophthalmology Service Military Hospital Moulay Ismail Meknes, Morocco

*Corresponding author: A. El Ouafi
DOI:10.21276/sjmps.2019.5.2.12

Abstract

Introduction: Von Hippel-Lindau disease (VHL) is a multi-systemic disease characterized by abnormal multiplication of blood vessels, with haemangioblastomas and cysts, as well as other neformations in the blood. Several organs. We report the case of a patient; we try to put the point on this pathology. Case Report: 14-year-old patient, consults for a BAV of the OD whose examination finds an intra vitreous haemorrhage, retinal capillary haemangioma and a lower exudative retinal detachment. The patient received an IVT of anti VEGF initially followed by an endocular surgery. Postoperative visual acuity was not improved with a follow-up of 6 months. The clinical definition of VHL disease is based on the presence of two major lesions, one of which is hemangioblastoma. The absence of family history, or a single injury in the presence of a family history. Complementary examination is based on angiography to fluoroescine. Complications can range from simple exudates to DR or even phytse of the globe. The treatment is essentially based on argon laser coagulation, cryotherapy, anti-VEGF and retinovitreal stage of complications. Conclusion: VHL is a hereditary disease with multi-systemic involvement, hence the interest of an examination complete follow-up, regular monitoring and genetic counseling in any patient suspected of having the disease as well as his family.

Keywords: Von. Hippel-Lindau, disease, (VHL).

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

Von Hippel Lindau disease (VHL) is a syndrome precancerous family with autosomal dominant inheritance, several organs can be affected: eye, CNS, liver, kidney, spleen, pancreas ... Retinal angiomatosis is the manifestation eye piece the most common. The diagnosis of this condition is clinical, confirmed by genetics. Treatment and prognosiss visual depend on the location of the hemangiomata and the occurrence of complications.

We report the case of a patient followed for the disease from VHL. Through this observation, we try to put the point on this pathology, in order to understand its physiopathology, recognize the means of clinical and paraclinical diagnosis, complications and therapeutic.

CASE REPORT

A 14-year-old patient from a consanguineous marriage consults for a decrease in the visual acuity of the right eye whose examination finds a visual acuity that cannot be improved to see the hand move, a normal anterior segment, a fund of the eye showing inferior vitreous hemorrhage with a juxtapapillary capillary haemangioma and a lower exudative retinal detachment (DR) (Fig-1). In the left eye, visual acuity is at 10/10 and the rest of the exam is strictly normal.

Fluorescein angiography is performed and confirms the diagnosis with the presence of retinal angiomatosis. Ocular ultrasound shows intra vitreous haemorrhage and retrohyaloid dense lower with membrane extensive fibrovascular associated with a tractional DR localized inferior (Fig-2). Abdominal ultrasound shows the presence of right renal cyst. A brain MRI does not show no lesions in the central nervous system. The patient received an intravitreous injection of anti-VEGF first followed by endocular surgery.

Postoperative visual acuity has not been improved with a minimum of six months.
**Discussion**

Von Hippel-Lindau disease is a multi-systemic disease autosomal dominant, characterized by a multiplication Abnormal blood vessels, with hemangioblastomas and cysts, as well as other neoformations in several organs. With the exception of renal cell carcinoma clear all these tumors are benign. The incidence is 3 per 100,000 and the average age of discovery is 25 years. The disease is due to a mutation of the VHL gene, which is part of tumor suppressor genes located on the short arm of the Ch3 [1, 2]. The six major lesions are hemangioblastoma of the neuraxis (mainly cerebellum and spinal cord) [3], hemangioblastoma of the retina, clear cell renal cancer and / or renal cysts [4], pheochromocytoma [5], cysts and / or pancreatic neuroendocrine tumors [6] and tumor endolymphatic sac [7]. The clinical definition is based on the presence of two major lesions including a hemangioblastoma in the absence of family history, or a single injury in the presence of a family history. Differential diagnosis essentially represented by the sporadic forms of tumors observed during VHL disease, it is necessary to systematically search for the condition, especially in a subject young or when they are multiple [8]. Regarding ocular involvement, retinal hemangioblastoma is characteristic and indicative of the disease in 30% of case [1]. It manifests itself either by an endophytic hemangioma;

It starts in chronological order by a small lesion red located in the capillary bed between an arteriolar and avenule, becoming a small nodule well delimited, there after a round orange-yellow mass with dilatation and tortuosity of the feeder artery and drainage vein for at last, become a white fibrous angioma, devoid of vessels; or a juxtapapillary exophytic hemangioma, less frequent, from the external retina [1]. Angiography at the fluorescein shows an early hyper fluorescence and ablate flight. Complications are represented by hard exudates surrounding the tumor or macular [9], macular edema and cellophane maculopathy, retinal detachment tractive, rhegmatogenic or exudative, intravitreal hemorrhage, secondary glaucoma and phthisis of the globe. The classification de Vail [9] defined 4 stages,

Stage I: Formation of angiomas and retinal arteriovenous dilatation,

Stage II: Appearance of haemorrhages and lipid deposits forming a macular star or retinitis circled around the tumor

Stage III: Massive exudation and detachment of the retina and

Stage IV: Absolute glaucoma, uveitis and visual loss.

The management of ocular involvement, includes severe modalities, including photo argon laser coagulation for small peripheral lesions [10], with the condition of absence fibrosis and exaggerated vitreomacular tractionst [11], intense and long impacts of 200 to 400 µm (0.5 to 1 second) to penetrate deeply into the angioma, they are repeated as necessary until the sustainable laundering of the angioma, it is necessary to avoid the vein of drainage with possibility impact on the feeder artery to reduce flow, the index of success is the regression of exudation, fibrosis, and the normalization of the caliber of the vessels. Cryotherapy
can be helpful for larger peripheral lesions size or in case of associated exudative retina detachment [9]. Brachytherapy reserved for larger lesions [12–14]. Retinovitreal surgery is being considered for severe cases of retinal capillary haemangioblastomas associated with serous DR, vascularized pre-retinal fibrosis or not and neo-vessels on the tumor or pre-papillary [14–17]. And finally, anti-VEGF systemically [18] or intravitreal [14] but of low efficiency. Disease surveillance should be annual, and should include a physical, ophthalmologic examination from 5 years, and half-yearly between 10 and 30 years, an ultrasound scan from 16 years, and 24h urine to detect pheochromocytoma from 10 years old. Screening every two years with abdominal and cerebral MRI from the age of 15 years old. Genetic counseling is indicated in all patients with whom the disease is suspected and with their families.

**CONCLUSION**

VHL disease is a hereditary condition with multi systemic where the interest of a complementary examination comprehensive, regular monitoring and genetic counseling in any patient whose disease is suspected.

**REFERENCES**


